Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real‐life study in Brazil
| Autor: | Adele Schwartz Benzaken, Fernanda Rick, Vivian Iida Avelino-Silva, Ana Roberta Pati Pascom, Gerson Fernando Mendes Pereira, Nazle M. C. Veras, Mariana Veloso Meireles, Rosana Egg Pinho, Filipe de Barros Perini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
antiretroviral treatment
Adult Male medicine.medical_specialty Efavirenz Adolescent Anti-HIV Agents efficacy Short Report Context (language use) HIV Infections real‐life Lower risk antiretroviral regimen Cohort Studies 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Short Reports cumulative viremia Internal medicine medicine Humans 030212 general & internal medicine Viremia Child Retrospective Studies 030505 public health business.industry Public Health Environmental and Occupational Health Lamivudine virus diseases HIV Middle Aged Atazanavir CD4 Lymphocyte Count Regimen Infectious Diseases chemistry Anti-Retroviral Agents Dolutegravir HIV-1 Female 0305 other medical science business Viral load Brazil medicine.drug |
| Zdroj: | Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| Popis: | Introduction The relative efficacy of different antiretroviral (ART) regimens has been extensively evaluated in the context of clinical trials, using HIV viral load (VL) measurements at pre‐specified timepoints after ART onset. However, data from real‐life studies using combined longitudinal measurements of cumulative viraemia are scarce. This study aimed to address the independent effect of different ART regimens on HIV cumulative viraemia over the first 12 months after treatment initiation, using programmatic data from the Ministry of Health of Brazil. Methods Retrospective cohort study analysing cumulative viraemia under the most frequently used ART regimens in Brazil (tenofovir, lamivudine and dolutegravir (regimen 1); tenofovir, lamivudine and efavirenz (regimen 2); tenofovir, lamivudine and ritonavir‐boosted atazanavir (regimen 3)). Results and Discussion We included 112,243 patients >12 years old who received their first ART prescription between January 2014 and August 2017. Univariate analysis indicated that cumulative viraemia was significantly lower in patients receiving regimen 1 as compared with those receiving regimens 2 or 3 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |